INSTEAD: Induction in Sensitized Kidney Transplant Recipients Without Pre-existing Donor-specific antiboDies

Sponsor

University Hospital, Tours (Other)

Overall Status

Not yet recruiting

CT.gov ID

NCT05385432

Collaborator

(none)

244

Enrollment

Arms

Anticipated Duration (Months)

Study Details

Study Description

Brief Summary

Induction therapy decreases the rate of acute allograft rejection in kidney transplant recipients (KTRs) and is strongly recommended. Polyclonal lymphocyte-depleting antibodies and interleukin-2 receptor (IL2R) antagonists are therefore widely used around the world, with a leading position for rabbit anti-thymocyte globulin (rATG, Thymoglobulin®) and basiliximab (Simulect®), respectively. The actual immunological risk of the sensitized KTRs without donor specific antibodies (DSAs) is still debated. The benefit-risk equation of lymphocyte depleting antibodies (versus IL2R antagonists) is not known in sensitized KTRs without DSAs. This clinical trial will compare the efficacy and safety of basiliximab and rATG in sensitized KTR without pre-existing DSAs detected by Luminex.

Condition or Disease	Intervention/Treatment	Phase
Renal Transplant Rejection Induction Therapy	Drug: Rabbit Anti thymocyte globulin (rATG) Drug: Basiliximab	Phase 4

Detailed Description

Kidney transplantation is the first-line treatment of end stage renal disease, improving life expectancy and quality of life in comparison to dialysis. The success of transplantation is a consequence of major advances, especially the development of efficient immunosuppressive drugs. However, thousands of kidney transplants fail yearly around the world, and kidney allograft failure is known as an important case of end-stage renal disease, leading to increased morbidity, mortality and costs. To improve graft survival is therefore a priority, especially in a context of organ shortage.

Many risk factors of kidney graft loss have been identified but alloimmune response remains the first determinant of graft loss. This powerful donor specific immune response involves numerous effectors that may be harmful to the graft, such as T and B lymphocytes and antibodies. Those antibodies are mainly directed against human leucocyte antigens (HLA) and DSAs can be detected and identified in serum of sensitized KTRs. Alloreactivity T-cells and antibodies may induce distinct categories of acute and chronic graft damages. Lesions of rejection, recognized on tissue fragments sampling by percutaneous ultrasound-guided core needle graft biopsy, are classified and graded according to international Banff classification that is regularly updated. Two categories of biopsy-proven acute rejections (BPAR) are thus distinguished: T-cell mediated rejection (TCMR) and antibody-mediated rejection (ABMR). TCMR is a well-known risk factor of graft loss and also associated with subsequent de novo DSAs appearance. ABMR is considered as the first cause of kidney graft loss. In contrast to TCMR, that is usually sensitive to steroids, no treatment is able to completely block the production of DSA and reverse the process of ABMR, especially chronic ABMR. Prevent appearance of DSA and subsequent ABMR is therefore a major concern to improve kidney transplant outcome.

Appearance of DSA after transplantation (de novo DSA) depends mainly on number of HLA mismatches between donor and recipient and level of immunosuppression. Regarding immunosuppression, two clinical trials have reported an increased incidence of de novo DSA in patients receiving a calcineurin inhibitor-free maintenance treatment. In addition, some retrospective studies have suggested that mycophenolic acid would be more efficient to prevent de novo DSA formation. Standard-of-care for maintenance immunosuppression is therefore a combination of anticalcineurin (tacrolimus has widely replaced cyclosporin over last two decades), mycophenolic acid (mycophenolate mofetil or enteric-coated mycophenolate sodium) and steroids. Data about induction therapy (i.e. initial immunosuppressive treatment given during the first post-transplantation week) and risk of de novo DSA and ABMR are scarce.

Induction therapy is a pivotal component of the immunosuppressive treatment. It has decreased the rate of acute allograft rejection in KTRs and is strongly recommended. Polyclonal lymphocyte-depleting antibodies and interleukin-2 receptor (IL2R) antagonists are thus widely used around the world, with a leading position for rabbit anti-thymocyte globulin (rATG, Thymoglobulin®) and basiliximab (Simulect®), respectively. Today, these two induction treatments are used in common practice in kidney transplantation (rATG since 1984 and basiliximab since 2003). According to international KDIGO recommendations, IL2R antagonists are the first-line induction therapy in low-immunological risk no sensitized recipients (level 1, grade A), while immunosuppressive intensification using lymphocyte depletive agents is warranted in high-immunological KTRs (level 2, grade A). This intensification is supported by two randomized clinical trials that found rATG as more efficient to prevent acute rejection in recipients with a high immunological risk.

The current concern is that the definition of "immunological risk" used in those studies and international recommendations is no longer in line with current clinical practices. Indeed, immunological risk was estimated by the number of previous transplantations, recipient age, donor age, ethnicity, number of HLA mismatches and level of sensitization (calculated panel-reactive antibodies (cPRA) > 30%), based on cytotoxicity and ELISA techniques. Nowadays, highly sensitive single HLA-antigen flow bead (SAB) assays have replaced cytotoxicity and ELISA techniques in all French histocompatibility laboratories to detect low amounts of anti-HLA antibodies and accurately determine their specificity. It is therefore possible to characterize with a great precision whether a KTR is sensitized (i.e. presence of any anti-HLA antibody, irrespective of its specificity) and has anti-HLA antibody specific for DSA. Hence, the broad use of SAB assays has split sensitized KTRs in two distinct groups: those with at least one pre-transplant DSA, who have undoubtedly a high risk of BPAR and graft loss, and those without DSA. The actual immunological risk of the sensitized KTRs without DSA is still debated. Some studies have suggested that the presence of non-donor specific anti-HLA antibodies would represent an intermediate risk for graft loss and antibody mediated rejection and others that these antibodies did not affect graft outcome and risk of BPAR. A prospective study that compared rATG and basiliximab has recently confirmed that rATG should be used in sensitized KTRs with low amount of DSA detectable using SAB assay. Finally, the benefit-risk equation of lymphocyte depleting antibodies (versus IL2R antagonists) remains unknown only in sensitized KTRs without DSA.

Address this concern is very important because rATG has the potential to induce long lasting CD4+ T-cell depletion which may last for many months or even for many years. This prolonged CD4 T-cell lymphopenia has been shown to be associated with an increase of morbidity and mortality after renal transplantation. Indeed, profound CD4 T-cell lymphopenia (i.e. less than 200-/mm3) exposes to an increase of viral infection and rATG has been identified as a risk factor for BK virus (BKv) replication and cytomegalovirus (CMV) infection. The increase of the risk of post-transplant lymphoproliferative disorder and/or solid cancer in patients treated with rATG compared to the use of IL2R antagonists is still under debate. Because of the potential side effects related to rATG, the use of lymphocyte depleting agents should be limited only to patients who may benefit from its use compared to IL2R antagonists. Some kidney transplant centers have recently decided to use basiliximab instead of rATG in sensitized KTR without DSA before transplantation, in order to decrease the risk of infection and malignancies. Investigators puslished a monocentric case control study that suggested that basiliximab was associated with an unusual high risk of rejection and DSA appearance in this specific population. Similar alert regarding basiliximab has been recently reported in a small prospective study even though lack of power precludes any definitive conclusions. The prescription of induction treatment is currently heterogeneous according to the centers. These results highlight the urgent need of a new clinical trial to compare basiliximab and rATG in sensitized KTR without pre-existing DSAs.

Study Design

Study Type:

Interventional

Anticipated Enrollment :

244 participants

Allocation:

Randomized

Intervention Model:

Parallel Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

Induction in Sensitized Kidney Transplant Recipients Without Preexisting Donor-specific antiboDies: a Randomized Multicentre Trial Between a Lymphocyte Depleting and Basiliximab.

Anticipated Study Start Date :

Sep 15, 2022

Anticipated Primary Completion Date :

Dec 15, 2024

Anticipated Study Completion Date :

Dec 15, 2027

Arms and Interventions

Arm	Intervention/Treatment
Experimental: rabbit antithymocyte globulin (rATG) The infusion of rATG (Thymoglobulin® (1.5mg/kg/day, maximum daily dose: 100 mg)) starts just after the randomization pre-operatively on a functional arteriovenous fistula or a high-flow venous catheter during 3 to 7 days until efficient tacrolimus level is obtained. The recommended initial tacrolimus dose is Prograf® 0.1mg/kg/day twice day.	Drug: Rabbit Anti thymocyte globulin (rATG) The infusion of rTAG (Thymoglobulin® (1.5mg/kg/day, maximum daily dose: 100 mg)) starts just after the randomization pre-operatively on a functional arteriovenous fistula or a high-flow venous catheter during 3 to 7 days until efficient tacrolimus level is obtained. Other Names: Maintenance immunosuppressive regimen is the same in experimental and control groups combining tacrolimus, mycophenolate mofetil (MMF) or enteric-coated mycophenolate sodium (EC-MPS) and steroids
Active Comparator: Basiliximab The infusion of Basiliximab (Simulect® (20mg)) starts before the surgery on peripheral vein for 15 minutes and the second infusion at day 4.	Drug: Basiliximab Simulect® IV 40mg D0 and D4 Other Names: Maintenance immunosuppressive regimen is the same in experimental and control groups combining tacrolimus, mycophenolate mofetil (MMF) or enteric-coated mycophenolate sodium (EC-MPS) and steroids

Arm

Intervention/Treatment

Experimental: rabbit antithymocyte globulin (rATG)

The infusion of rATG (Thymoglobulin® (1.5mg/kg/day, maximum daily dose: 100 mg)) starts just after the randomization pre-operatively on a functional arteriovenous fistula or a high-flow venous catheter during 3 to 7 days until efficient tacrolimus level is obtained. The recommended initial tacrolimus dose is Prograf® 0.1mg/kg/day twice day.

Drug: Rabbit Anti thymocyte globulin (rATG)

The infusion of rTAG (Thymoglobulin® (1.5mg/kg/day, maximum daily dose: 100 mg)) starts just after the randomization pre-operatively on a functional arteriovenous fistula or a high-flow venous catheter during 3 to 7 days until efficient tacrolimus level is obtained.

Other Names:

Maintenance immunosuppressive regimen is the same in experimental and control groups combining tacrolimus, mycophenolate mofetil (MMF) or enteric-coated mycophenolate sodium (EC-MPS) and steroids

Active Comparator: Basiliximab

The infusion of Basiliximab (Simulect® (20mg)) starts before the surgery on peripheral vein for 15 minutes and the second infusion at day 4.

Drug: Basiliximab

Simulect® IV 40mg D0 and D4

Other Names:

Maintenance immunosuppressive regimen is the same in experimental and control groups combining tacrolimus, mycophenolate mofetil (MMF) or enteric-coated mycophenolate sodium (EC-MPS) and steroids

Outcome Measures

Primary Outcome Measures

Incidence of biopsy-proven acute rejection (BPAR) at year 1 [during the first post-transplantation year]
Incidence of BPAR (treated suspicious TCMR and confirmed TCMR with grade ≥ 1 and ABMR) in rATG and basiliximab groups, determined after blind central reading according to Banff 2019 classification.

Secondary Outcome Measures

Incidence of BPAR in rATG and basiliximab groups at year 3. [at year 3]
Incidence of BPAR (TCMR and ABMR) in rATG and basiliximab groups at year 3.
Incidence of composite criteria [at year 3]
Incidence of composite criteria including BPAR, death and graft loss (retransplantation or dialysis) at year 3
Incidence of confirmed TCMR and ABMR in rATG and basiliximab groups at year 1 and 3. [at year 1 and 3]
Incidence of confirmed TCMR and ABMR in rATG and basiliximab groups at year 1 and 3.
Incidence of de novo DSA in rATG and basiliximab groups at year 1 and 3 [at year 1 and 3]
Incidence of de novo DSA in rATG and basiliximab groups at year 1 and 3
Incidence of CMV viremia, CMV disease, BKv viremia and BKv nephropathy in rATG and basiliximab groups at year 1 and 3. [at year 1 and 3]
Incidence of CMV viremia, CMV disease, BKv viremia and BKv nephropathy in rATG and basiliximab groups at year 1 and 3.
Estimated glomerular filtration rate (eGFR) according to MDRD formula and proteinuria/creatinuria ratio in rATG and basiliximab groups at year 1 and 3 [at year 1 and 3]
Estimated glomerular filtration rate (eGFR) according to MDRD formula and proteinuria/creatinuria ratio in rATG and basiliximab groups at year 1 and 3
Incidence of primary and secondary outcomes (BPAR, TCMR, ABMR, death, graft loss, de novo DSA, CMV and BKv infections, eGFR) in subgroups defined by rank of transplantation. [at year 1 and 3]
ncidence of primary and secondary outcomes (BPAR, TCMR, ABMR, death, graft loss, de novo DSA, CMV and BKv infections, eGFR) in subgroups defined by rank of transplantation.
Health-Economics endpoints: Incremental Cost Utility Ratio [at year 1]
Incremental Cost Utility Ratio (ICUR) estimating the "cost per QALY gained", at 12 months, from the French Healthcare Insurance perspective, of rATG in comparison to basiliximab.
Health-Economics endpoints: Incremental Cost Effectiveness Ratio [at year 1]
Incremental Cost Effectiveness Ratio (ICER) estimating the "cost per prevented BPAR" at 12 months, from the French Healthcare Insurance perspective, of rATG in comparison to basiliximab.

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years to 79 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Patients aged between 18-79
At least one anti-HLA antibody identified by the Luminex Single Antigen test with MFI ≥ 2000
Graft incompatibility rate (TGI) <85%
Ability for participant to comply with the requirements of the study
Written informed consent obtained from the participant
Participants covered by or entitled to social security

Exclusion Criteria:

DSA (positive virtual crossmatch with MFI threshold at 500)
Patient under legal protection, under guardianship or curatorship
Combined transplantation
Beneficiaries of kidney transplants from donations after uncontrolled circulatory death (Maastricht II)
Incompatible ABO transplantation
Leukopenia lower than 3000/mm3
Donor EBV positive / recipient EBV Negative
History of solid cancer (< 2 years), except to skin carcinoma (squamous-cell and basal-cell carcinoma)
History of lymphoma
Patients with severe uncontrolled systemic infection or severe allergy requiring acute or chronic treatment; Aspartate aminotransferase (ASAT), Alanine Amino Transferase (ALAT) or bilirubin greater than 3 times normal
Known hypersensitivity or contra-indication to rabbit proteins, basiliximab, tacrolimus, mycophenolic acid, or any of the product excipients.
Pregnant or breastfeeding woman, or woman of childbearing potential not using an effective method of contraception, or having a desire to conceive within 12 months of randomization
Concurrent participation in any interventional clinical trial conducted by the recipient